The COX-2 inhibitors: A reasoned review of the data

Swiss Medical Weekly

Volumn 135, Issue 29-30, 2005, Pages 419-424

  Simon, Lee S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular effects; COX 2 selective inhibitors; Hypertension; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACOXIB; PIROXICAM; ROFECOXIB; SULINDAC; UNCLASSIFIED DRUG; VALDECOXIB;

ALZHEIMER DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLON POLYP; DOSE RESPONSE; DRUG USE; EDEMA; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HEART INFARCTION; HUMAN; HYPERTENSION; MEDICAL PRACTICE; META ANALYSIS; MUSCULOSKELETAL DISEASE; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 24944465163     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, van de Putte LB, Abramson SB Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000;160:913-20.
2. Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, et al. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000;27:1338-1340
3. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, et al. Controversies in COX-2 selective inhibition: report from a consensus conference 2002. J Rheumatol 2002;29:1501-10.
4. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA. Basic biology and clinical application of cyclooxygenase-2. Arthritis Rheum 2000;43::4-13.
5. Husni ME, Simon LS. Additional considerations on the use of NSAIDs. In: Tsokos GC. Modern Therapeutics in Rheumatic Diseases. Totowa, New Jersey: Humana Press; 2002. p. 47-65.
6. Bombardier, C, Laine, L, Reicin, A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520.
7. Silverstein, FE, Faich, G, Goldstein, JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial. JAMA 2000;284:1247.
8. Mukherjee, D, Nissen, SE, Topol, EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954.
9. Caughey, GE, Cleland, LG, Penglis, PS, et al. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001;167:2831.
10. Cheng, Y, Austin, SC, Rocca, B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296:539.
11. Topol, EJ. Arthritis medicines and cardiovascular events - "House of Coxibs". JAMA 2005;293:366.
12. Furberg, CD, Psalty, BM, FitzGerald, GA. Parecoxib, valdecoxib, and cardiovascular risk. Circulation 2005;111:249.
13. Topol, EJ, Falk, GW. A coxib a day won't keep the doctor away. Lancet 2004;364:639.
14. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, De-Marco S, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-17.
15. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003;107:405-9.
16. FitzGerald GA. Mechanisms of platelet adtivation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68:11B-15B.
17. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
18. White WB, Faich G, Borer JS, Makuch RW. Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003;92:411.
19. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280.
20. United States Food and Drug Administration. FDA alert for practitioners on Celebrex (celecoxib). http://www.fda.gov/ cder/drug/infopage/celebrex/ celebrex-hcp.htm, accessed Jan 3, 2004.
21. Moore RA, Derry S, Makinson GT, et al. Tolerability and adverse events in clinical trial sof celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta analysis of information for company clinical reports Arthritis Res Ther 2005;7:R644-R655.
22. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490-6.
23. White WB, Strand V, Toberts R, et al. Effecits of the cycoloxygenase 2 specific inhibitor valdecoxib versus non steroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 2004;11:244-50.
24. Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. Pain 2004;111:286-96.
25. Merck news release. www.merck.com/newsroom/press_releases/product/ 2004_0930.html accessed September 30, 2004.
26. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al., and the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
27. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
28. Antithrombotic Trialists' Collaboration, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
29. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, et al. Adenoma Prevention with Celecoxib (APC) Study Investigairin componentors. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80.
30. FDA Advisory Committee Briefing Document Celecoxib and Valdecoxib Cardiovascular Safety. January 12, 2005-06-28.
31. Mamdani, M, Juurlink, DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363:1751.
32. Whelton, A, Fort, JG, Puma, JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85.
33. Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol 2004;31:1143.
34. Solomon, DH, Schneeweiss, S, Levin, R, Avorn, J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004;44:140.
35. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994 Aug 15;121:289-300.
36. Sowers, JR, White WB, Pitt B, Whelton A, Simon LS, et al., for the Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med 2005;165:161-8.
37. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheuamtoid arhtiritis: a randomized controlled comparison with placebo and naproxen Rheumatology 2002 41:1008-16.
38. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, et al. The antiinflammatory and upper gastrointestinal effects of celecoxib in rhematoid arthritis: A randomized, controlled trial. JAMA 1999;282:1921-8.
39. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;125:1481.
40. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, et al. Complications of the COX-2 Inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352: 1081-91.
41. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111.
42. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099.
43. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105.
44. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118.
45. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068.
46. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481.
47. Shaya FT, Blume SW, Blanchette CM, et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005;165: 181-6.
48. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157.
49. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-4.
50. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascuolar events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-9.
51. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-81.
52. Crofford LJ, Oates JC, McCune WI, et al. Thrombosis in patients with connective tissue disease treated with specific COX-2 inhibitors: a report of four cases. Arthritis Rheum 2000;43: 1891-6.
53. FitzGerald GA, Patrono C. Drug therapy: the coxibs, selective inhibitors of cyclooxygenase-2. NEJM 2001;345:433-42.
54. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751-3.
55. Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000;11:382-7.
56. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:1293-304.
57. FDA Arthritis Advisory Committee Meeting February 8 2001 Gaithersburg MD.
58. FDA Arthritis Advisory Committee Meeting February 7, 2001, Gaithersburg, MD.
59. Khan KN, Stanfield KM, Harris RK, Baron DA. Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 2001;23:321.
60. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients >65 years of age with systemic hypertension and osteoarthritis Am J Cardiol 20021;90:959-63.
61. Farkouh, ME, Kirshner, H, Harrington, RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675.
62. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology. 1989;96(2 pt 2 suppl):647-55.
63. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50:2433-40.
64. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 2004;328:1415-6.
65. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther. 2004;19: 1189-98.
66. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
67. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124: 288-92.